- Home
- OCGN vs DAVA Comparison
OCGN vs DAVA Comparison
Compare OCGN & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCGN | DAVA |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 356.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OCGN | DAVA |
|---|---|---|
| Price | $1.45 | $6.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $16.33 |
| AVG Volume (30 Days) | ★ 3.2M | 1.2M |
| Earning Date | 11-05-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.26 |
| EPS | N/A | ★ 0.25 |
| Revenue | $5,370,000.00 | ★ $1,015,391,026.00 |
| Revenue This Year | $32.40 | N/A |
| Revenue Next Year | N/A | $3.62 |
| P/E Ratio | ★ N/A | $27.58 |
| Revenue Growth | ★ 14.26 | 1.07 |
| 52 Week Low | $0.52 | $6.02 |
| 52 Week High | $1.90 | $34.94 |
Technical Indicators
Market Signals| Indicator | OCGN | DAVA |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 49.13 |
| Support Level | $1.35 | $6.43 |
| Resistance Level | $1.26 | $6.78 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 78.43 | 79.31 |
Price Performance
Historical ComparisonAbout OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.